Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SAN FRANCISCO, Aug. 22, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in TechnipFMC plc (NYSE:FTI) of the October 2, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of FTI between April 27, 2017 and July 24, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/FTI
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On July 24, 2017, FTI announced in its Form 8-K filed with the U.S. Securities and Exchange Commission that it would restate certain unaudited interim condensed consolidated U.S. GAAP financial statements. Specifically, FTI determined that it would restate financial statements for March 31, 2017 and for the three months ended March 31, 2017 included in the Company’s quarterly report on Form 10-Q, previously filed with the SEC on May 4, 2017.
The Company explained “net income attributable to the Company in the quarter ending March 31, 2017 was overstated by $209.5 million ($0.45 per share).”
This news drove the price of FTI shares down on unusually heavy volume on July 25, 2017.
Recently, on August 4, 2017, FTI filed its amended Form 10-Q for the quarterly period ended March 31, 2017. Defendants reduced previously reported net income attributable to TechnipFMC from $190.8 million to a net loss of $18.7 million for that period.
“We’re focused on the magnitude of management’s improper accounting that, as corrected, wipes out previously reported Q1 2017 net income,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding FTI should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
